Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

PURPOSE: In 2017, the Geneva Alzheimer’s disease (AD) strategic biomarker roadmap initiative proposed a framework of the systematic validation AD biomarkers to harmonize and accelerate their development and implementation in clinical practice. Here, we use this framework to examine the translatabili...

Descripción completa

Detalles Bibliográficos
Autores principales: Bischof, Gérard N, Dodich, Alessandra, Boccardi, Marina, van Eimeren, Thilo, Festari, Cristina, Barthel, Henryk, Hansson, Oskar, Nordberg, Agneta, Ossenkoppele, Rik, Sabri, Osama, Giovanni, B Frisoni G, Garibotto, Valentina, Drzezga, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175320/
https://www.ncbi.nlm.nih.gov/pubmed/33590274
http://dx.doi.org/10.1007/s00259-020-05156-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175320/
https://www.ncbi.nlm.nih.gov/pubmed/33590274
http://dx.doi.org/10.1007/s00259-020-05156-4

Ejemplares similares